Article in Molecular cancer research : MCR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
14 authors.
Dianna H HuismanEppley Institute, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, Nebraska.ORCID 0000-0002-1183-5391
Deepan ChatterjeeEppley Institute, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, Nebraska.ORCID 0000-0001-7997-7014
Robert A SvobodaDepartment of Pathology, Microbiology, and Immunology, University of Nebraska Medical Center, Omaha, Nebraska.ORCID 0009-0003-6004-0768
Heidi M VieiraEppley Institute, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, Nebraska.ORCID 0000-0003-1555-2281
Abbie S IrelandDeparment of Molecular Cancer Biology, Duke University, Durham, North Carolina.ORCID 0000-0002-4178-7239
Sydney SkupaEppley Institute, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, Nebraska.ORCID 0000-0002-8933-6015
James W AskewEppley Institute, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, Nebraska.ORCID 0000-0002-3110-8976
Danielle E FrodymaEppley Institute, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, Nebraska.ORCID 0000-0002-8120-6953
Luc GirardHamon Center for Therapeutic Oncology Research, Department of Pharmacology, Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas.ORCID 0000-0002-6688-5281
Kurt W FisherDepartment of Pathology, Microbiology, and Immunology, University of Nebraska Medical Center, Omaha, Nebraska.ORCID 0000-0002-8391-390X
Michael S KaretaCancer Biology and Immunotherapies Group, Sanford Research, Sioux Falls, South Dakota.ORCID 0000-0002-6980-9065
John D MinnaHamon Center for Therapeutic Oncology Research, Department of Pharmacology, Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas.ORCID 0000-0002-7776-0767
Trudy G OliverDeparment of Pharmacology and Cancer Biology, Duke University, Durham, North Carolina.ORCID 0000-0003-2082-2397
Robert E LewisEppley Institute, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, Nebraska.ORCID 0000-0002-3616-2971
Funding
UNMC Structural Biology CoreP20GM103427 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI PAUL L SORGEN · 2012 to 2026
$59.2M
UNIVERSITY OF TEXAS--SPORE IN LUNG CANCERP50CA070907 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI HEYMACH, JOHN V., MINNA, JOHN D. · 1996 to 2024
$57.4M
UNMC/EPPLEY CANCER CENTER SUPPORT GRANTP30CA036727 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Joann B. Sweasy · 1985 to 2026
$55.0M
Target Validation CoreP20GM121316 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Robert E. Lewis · 2018 to 2026
$23.5M
Coordinating center for the NCI small cell lung cancer research consortiumU24CA213274 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Lauren Averett Byers, JOHN D. MINNA · 2017 to 2026
$12.9M
CHEMICAL CARCINOGENESIS &CANCER BIOLOGYT32CA009476 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Jennifer D. Black · 1988 to 2026
$6.2M
Regulation of RBP Function during EMTR01CA277495 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Robert E. Lewis · 2024 to 2026
$1.3M
Novel Mechanisms Controlling SCLC Tumor InitiationR21CA256638 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI LEWIS, ROBERT E. · 2021 to 2022
$398k
Molecular control of tumor-initiating cells in Ras-driven cancersF30CA268766 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI VIEIRA, HEIDI · 2023 to 2025
$116k
National Cancer Institute (NCI) P30CA036727National Cancer Institute (NCI) R21CA256638National Cancer Institute (NCI) U24CA213274National Institute of General Medical Sciences (NIGMS) NIH GM121316 and CA277495NCI NIH HHS F30 CA268766NCI NIH HHS P30 CA036727NCI NIH HHS P50 CA070907NCI NIH HHS R01 CA277495NCI NIH HHS R21 CA256638NCI NIH HHS T32 CA009476NCI NIH HHS U24 CA213274Nebraska Department of Health and Human Services (Nebraska DHHS) LB 506NIGMS NIH HHS P20 GM103427NIGMS NIH HHS P20 GM121316U.S. Department of Defense (DOD) LC210123
6 · The paper itself
Abstract
Small cell lung carcinoma (SCLC) tumors are heterogeneous, with a subpopulation of cells primed for tumor initiation. In this study, we show that kinase suppressor of Ras 2 (KSR2) promotes the self-renewal and clonogenicity of SCLC cells. KSR2 is a molecular scaffold that promotes Raf/MEK/ERK signaling. KSR2 is preferentially expressed in the ASCL1 subtype of SCLC (SCLC-A) tumors and is expressed in pulmonary neuroendocrine cells, one of the identified cells of origin for SCLC-A tumors. The expression of KSR2 in SCLC and pulmonary neuroendocrine cells was previously unrecognized and serves as a novel model for understanding the role of KSR2-dependent signaling in normal and malignant tissues. Disruption of KSR2 in SCLC-A cell lines inhibits the colony-forming ability of tumor-propagating cells in vitro and their tumor-initiating capacity in vivo. The effect of KSR2 depletion on self-renewal and clonogenicity is dependent on the interaction of KSR2 with ERK. These data indicate that the expression of KSR2 is an essential driver of SCLC-A tumor-propagating cell function and therefore may play a role in SCLC tumor initiation. These findings shed light on a novel effector promoting initiation of SCLC-A tumors and a potential subtype-specific therapeutic target. IMPLICATIONS: Manipulation of the molecular scaffold KSR2 in SCLC-A cells reveals its contribution to self-renewal, clonogenicity, and tumor initiation.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
KSR2 Promotes Self-Renewal and Clonogenicity of Small Cell Lung Carcinoma. · full record | OpenQuestion